COVID-19 vaccine sales push Moderna to $12B profit in 2021
By TOM MURPHY
AP Health Writer
COVID-19 vaccine sales jumped 44% for Moderna in the final quarter of 2021, and the drugmaker expects demand for booster shots to fuel more growth in 2022. Moderna said Thursday that it has signed purchase agreements for about $19 billion in sales for 2022 with options for an additional $3 billion that would cover any updated boosters the company is developing. Company leaders say they firmly believe booster shots will be required next fall, and they expect sales to be larger in the second half of the year. Shares of the Cambridge, Massachusetts, company soared Thursday.